Core Viewpoint - The licensing agreement between Xiansheng Pharmaceutical and Wangshan Wangshui for dextromethorphan hydrobromide is a significant development, as it positions Xiansheng to potentially launch the world's first nucleoside-based drug for RSV infections in Greater China [1] Group 1: Licensing Agreement - Xiansheng Pharmaceutical has entered into a licensing agreement with Wangshan Wangshui for dextromethorphan hydrobromide [1] - The agreement grants Xiansheng exclusive rights to the drug in Greater China for treating respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections [1] Group 2: Drug Approval Status - Dextromethorphan hydrobromide tablets have already received regular approval in China for treating mild to moderate COVID-19 infections in adults [1] - The drug is expected to become the first approved nucleoside-based treatment for RSV globally [1]